Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial

Richard E. Pratley, Adie Viljoen(Lister Hospital), J Lüdemann, Ildiko Lingvay(Southwestern Medical Center), Camilla Andreassen(Novo Nordisk (Denmark)), Andrea Navarria(Novo Nordisk (Denmark)), Vanita R. Aroda(Brigham and Women's Hospital)
The Lancet Diabetes & Endocrinology
February 1, 2018
10.1016/s2213-8587(18)30024-x
Cited by 758

Related Papers

Hypoadiponectinemia in Obesity and Type 2 Diabetes: Close Association with Insulin Resistance and Hyperinsulinemia
|The Journal of Clinical Endocrinology & Metabolism|2001|3.4k
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
|New England Journal of Medicine|2023|2.6k
2. Classification and Diagnosis of Diabetes:<i>Standards of Care in Diabetes—2023</i>
|Diabetes Care|2022|2.4k
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
|Diabetes Care|2022|1.9k
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
|Diabetologia|2022|986